Share page on LinkedIn

Early Clinical

Early phase development services that will enable informed decision making for your drug development programme.

Innovative early clinical solutions that will advance your drug development strategy

  • 6

    Clinical research units across Europe and the USA
  • 894

    Early phase clinical trials over the last 5 years
  • 32,600

    Healthy volunteers and patients targeted

ICON is committed to the highest standards of excellence and scientific expertise in early clinical drug development.

We have extensive experience in the design, conduct, and interpretation of early phase first-in-human and proof of concept studies, providing the full suite of clinical pharmacology studies, all elements of a regulatory package programme, and translational early efficacy indication solutions in a range of study types including: 

  • Absorption, Metabolism, Excretion, (AME)

  • Bioavailability

  • Bioequivalence

  • Drug-drug interaction

  • Food Effect (FE)

  • Hepatic Impairment

  • Human Abuse Liability

  • Microdose

  • Multiple Ascending Dose (MAD)

  • Phase 1 First in human

  • Phase 1b/2a Proof of concept

  • Renal Impairment

  • Single Ascending Dose (SAD)

  • Thorough QT (TQT/) QTc

ICON’s early clinical services deliver full visibility and control to meet the requirements of increasingly complex clinical trial requirements. Our dedicated early phase specialists will engage with you to develop a trial that is best for your compound. Together we will build a tailored approach that leverages our clinical pharmacology expertise, extensive research facilities, early phase operational experience, and biometrics capabilities to conduct your trial within both healthy volunteers and patient populations. 

Our range of dedicated early phase clinical development services include:

Our dedicated early clinical experts have the experience to address the most demanding early phase drug development challenges including:

Increasing complexity of trials

Increasing complexity of trials

Delivery of reliable safety and efficacy data faster

Delivery of reliable safety and efficacy data faster

Finding the right clinical settings to support complex assessment

Finding the right clinical settings to support complex assessment

What’s happening in ICON